Sanofi and Regeneron Pharmaceuticals, Inc. have restructured their global discovery and development agreement for new immuno-oncology cancer treatments, providing for ongoing collaborative development of two clinical-stage bispecific antibody programs. This provides Sanofi increased flexibility to advance its early-stage immuno-oncology pipeline independently while Regeneron retains all rights to its other immuno-oncology discovery and development programs.   Sanofi will pay Regeneron $462 mi...